Sanara MedTech Inc. Common Stock (SMTI)

FairStock Score: 28/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach Sanara MedTech as a medical products company with a small but growing revenue base. In fiscal 2025, the year ended 2025-12-31, it reported revenue of $103.1M, up from $86.7M in fiscal 2024, yet net loss widened to $37.6M from $9.7M. The latest filed quarter, fiscal Q2 2026 ended 2026-06-30, showed revenue of $28.1M and a net loss of $452,864, while fiscal Q1 2026 ended 2026-03-31 had net income of $458,957. So profitability is not consistent; one quarter makes money, another loses a little. FairStock's Lynch screen finds no category because the company lost money in each of the last four years.

In plain English: Sanara MedTech sells surgical wound-care products to hospitals and clinics. Sales are growing, but the business has mostly lost money, including a large loss in fiscal 2025, and it carries high debt relative to its equity. At $35.14 on 2026-10-13, the shares look expensive compared with the company's current earnings and cash flow.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer